A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Dimethyl fumarate (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms INSPIRE
  • Sponsors Biogen
  • Most Recent Events

    • 13 Nov 2015 Planned End Date changed from 1 Jun 2019 to 1 Feb 2016 as per ClinicalTrials.gov record.
    • 13 Nov 2015 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2016 as per ClinicalTrials.gov record.
    • 13 Nov 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top